31 gene expression profile (Castle Biosciences)
86
Structured Review
Castle Biosciences
31 gene expression profile
31 Gene Expression Profile, supplied by Castle Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+profiling/31+expression+gene+profile/pm42279412-3-7-12
Average 86 stars, based on 1 article reviews
31 Gene Expression Profile, supplied by Castle Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+profiling/31+expression+gene+profile/pm42279412-3-7-12
Average 86 stars, based on 1 article reviews
31 gene expression profile - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
Gene Expression:Article Title: Malignant Transformation of Ocular Melanocytoma to Uveal Melanoma: A Clinicopathologic Review of Three Novel Unsuspected Cases of a Likely Under-Recognized Phenomenon, With Review of the Literature and Molecular Genetic Data. Article Snippet: • PURPOSE: To describe three cases of, and review the current knowledge regarding, malignant transformation of ocular melanocytoma (OM) to uveal melanoma (UM).. • DESIGN: Retrospective clinicopathological case series and review of the literature.. • METHODS: Clinical records and histopathology from three patients diagnosed with UM arising from a previously unsuspected OM were critically reviewed at a single academic institution. Article Title: Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions Article Snippet: .. The risk of metastatic development for patients with UM can also be predicted using the Article Title: Precision medicine and Treat-to-Target approach in atopic dermatitis: enhancing personalized care and outcomes Article Snippet: .. On the other hand, Castle Biosciences uses non-invasive skin scrapings and Article Title: Displacement of submacular hemorrhage with intravitreal tissue plasminogen activator following 27 gauge transvitreal fine needle aspiration biopsy for choroidal melanoma Article Snippet: .. Article Title: Commercial Diagnostics and Emerging Precision Medicine Technologies in Psoriasis and Atopic Dermatitis Article Snippet: In this review, we discuss the commercially available Mindera Health “Mind.PxTM” patch test to guide psoriasis biologic selection. .. We also explore ongoing clinical studies by Castle Biosciences examining Article Title: Precision medicine and Treat-to-Target approach in atopic dermatitis: enhancing personalized care and outcomes. Article Snippet: Two companies, Mindera Health and Casle Biosciences, are pioneering non-invasive technologies to m g u c ddress these challenges.33 Mindera Health developed the ind.PxTM dermal patch, which uses microneedles to col- ect RNA from skin samples. .. Machine learning and genetic iomarkers predict patient responses to specific psoriais biologics, reducing trial-and-error treatments.34 Clinical tudies (e.g., STAMP-2, MATCH) demonstrated its economic nd clinical benefits, showing high predictive accuracy n severe psoriasis cases, and reducing biological therapy osts.33 On the other hand, Castle Biosciences uses nonnvasive skin scrapings and Article Title: Adjuvant Therapy of Melanoma Article Snippet: .. ANDTrametinib 2 mg once daily vs. placebos for 12 months November 2012 July 2015 Crizotinib ( {"type":"clinical-trial","attrs":{"text":"NCT02223819","term_id":"NCT02223819"}} NCT02223819 ) 30 Open label phase II study in high-risk uveal melanoma as determined by Article Title: Comparative Analysis of Staging and Metastatic Risk Stratification Systems for Cutaneous Squamous Cell Carcinoma. Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Real-time Polymerase Chain Reaction:Article Title: Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions Article Snippet: .. The risk of metastatic development for patients with UM can also be predicted using the Polymerase Chain Reaction:Article Title: Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions Article Snippet: .. The risk of metastatic development for patients with UM can also be predicted using the Biomarker Discovery:Article Title: Commercial Diagnostics and Emerging Precision Medicine Technologies in Psoriasis and Atopic Dermatitis Article Snippet: In this review, we discuss the commercially available Mindera Health “Mind.PxTM” patch test to guide psoriasis biologic selection. .. We also explore ongoing clinical studies by Castle Biosciences examining Adjuvant:Article Title: Adjuvant Therapy of Melanoma Article Snippet: .. ANDTrametinib 2 mg once daily vs. placebos for 12 months November 2012 July 2015 Crizotinib ( {"type":"clinical-trial","attrs":{"text":"NCT02223819","term_id":"NCT02223819"}} NCT02223819 ) 30 Open label phase II study in high-risk uveal melanoma as determined by Immunopeptidomics:Article Title: Adjuvant Therapy of Melanoma Article Snippet: .. ANDTrametinib 2 mg once daily vs. placebos for 12 months November 2012 July 2015 Crizotinib ( {"type":"clinical-trial","attrs":{"text":"NCT02223819","term_id":"NCT02223819"}} NCT02223819 ) 30 Open label phase II study in high-risk uveal melanoma as determined by |